Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) gapped down before the market opened on Tuesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $610.86, but opened at $561.75. Regeneron Pharmaceuticals shares last traded at $558.22, with a volume of 229,725 shares trading hands. The biopharmaceutical […] - 2025-05-01 05:18:54
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target reduced by equities research analysts at Truist Financial from $1,004.00 to $975.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Truist Financial’s price target indicates a potential upside of 62.57% from […] - 2025-04-25 07:28:48
Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a hold rating to a strong-buy rating in a research note published on Tuesday,Zacks.com reports. Several other equities research analysts have also recently commented on REGN. JPMorgan Chase & Co. cut their price target on shares of Regeneron Pharmaceuticals from $1,100.00 to […] - 2025-04-25 07:28:48
(RTTNews) - Regeneron Pharma, Inc. (REGN), a biotechnology company, on Tuesday announced a major expansion of its manufacturing capacity through a new agreement with FujiFilm Diosynth Biotechnologies. The total investment is expected to be over $3 billion. - 2025-04-22 11:38:18
CreativeOne Wealth LLC bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 446 shares of the biopharmaceutical company’s stock, valued at approximately $318,000. Several other hedge funds have also bought […] - 2025-04-21 08:12:54
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN), Thursday announced that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application for EYLEA HD (aflibercept) Injection 8 mg for the treatment of retinal vein occlusion. - 2025-04-17 11:52:05
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price reduced by equities researchers at The Goldman Sachs Group from $1,019.00 to $917.00 in a research note issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s price target points to a potential upside […] - 2025-04-16 05:42:54
Three stocks which have generated 100-bagger returns for investors over the past 20 years are Booking Holdings (NASDAQ: BKNG), Apple (NASDAQ: AAPL), and Regeneron Pharmaceuticals (NASDAQ: REGN). Here's a look at how much a $1,000 investment into each of these stocks back then wou - 2025-04-05 07:23:00
Blair William & Co. IL reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 38.6% in the 4th quarter, HoldingsChannel.com reports. The firm owned 1,255 shares of the biopharmaceutical company’s stock after selling 788 shares during the period. Blair William & Co. IL’s holdings in Regeneron Pharmaceuticals were worth $894,000 at the […] - 2025-04-04 08:23:06
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price objective dropped by analysts at JPMorgan Chase & Co. from $1,100.00 to $1,000.00 in a report released on Monday,Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 62.07% […] - 2025-04-02 05:54:52
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) shares reached a new 52-week low on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $1,100.00 to $1,000.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Regeneron Pharmaceuticals traded as low as $618.51 and last traded at […] - 2025-04-02 05:12:49
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) have been given an average recommendation of “Moderate Buy” by the twenty-five analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, sixteen have issued a buy recommendation and […] - 2025-04-01 05:56:47
Independent Advisor Alliance raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 117.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 478 shares of the biopharmaceutical company’s stock after buying an additional 258 shares during the quarter. Independent Advisor Alliance’s holdings […] - 2025-03-19 07:42:48
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Capital Group Growth ETF (Symbol: CGGR) where we have detected an approximate $214.1 million dollar inflow -- that's a 2.2% increase week over week i - 2025-03-18 15:20:48
In early trading on Wednesday, shares of Applovin topped the list of the day's best performing components of the Nasdaq 100 index, trading up 9.3%. Year to date, Applovin has lost about 13.0% of its value.
And the worst performing Nasdaq 100 component thus far on the day is Re - 2025-03-12 14:53:06
Jones Financial Companies Lllp increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 107.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 812 shares of the biopharmaceutical company’s stock after acquiring an additional 421 shares during […] - 2025-03-10 08:06:59
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has received an average rating of “Moderate Buy” from the twenty-five analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation, sixteen have given a buy recommendation and two have assigned […] - 2025-03-07 06:59:02
Sigma Planning Corp grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 91.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 782 shares of the biopharmaceutical company’s stock after acquiring an additional 373 shares during the quarter. Sigma Planning […] - 2025-02-27 09:05:02
D.A. Davidson & CO. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 8.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 753 shares of the biopharmaceutical company’s stock after selling 68 shares during the quarter. D.A. Davidson & CO.’s […] - 2025-02-26 09:01:06
(RTTNews) - The U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application or sBLA for Dupixent (dupilumab) to treat adults with bullous pemphigoid, Regeneron Pharmaceuticals Inc. (REGN) and Sanofi (SNYNF, SNY) said in a stat - 2025-02-18 06:25:28
Kingsview Wealth Management LLC raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 16.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,002 shares of the biopharmaceutical company’s stock after acquiring an additional 142 […] - 2025-02-13 09:55:09
U.S. Capital Wealth Advisors LLC lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 80.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 429 shares of the biopharmaceutical company’s stock after selling 1,746 shares during the quarter. U.S. Capital […] - 2025-02-07 10:16:49
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) was upgraded by stock analysts at Leerink Partnrs from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports. REGN has been the subject of several other research reports. Wolfe Research started coverage on shares of Regeneron Pharmaceuticals in […] - 2025-02-07 06:28:44
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Invesco S&P 500 Momentum ETF (Symbol: SPMO) where we have detected an approximate $221.0 million dollar inflow -- that's a 4.9% increase week ove - 2025-02-04 16:05:12
(RTTNews) - Regeneron Pharmaceuticals (REGN) will host a conference call at 8:30 AM ET on Feb. 4, 2025, to discuss Q4 24 earnings results. - 2025-02-04 12:31:10
REGN institutional holdings
The following institutional investment holdings of REGN have been identified
Date
ETF ISIN/Name
Num Shares
Book value
Fatal error: Uncaught mysqli_sql_exception: Column 'Currency_Code' in field list is ambiguous in /var/www/liquidata/show_aggregate_holdings.php:119
Stack trace:
#0 /var/www/liquidata/show_aggregate_holdings.php(119): mysqli->query()
#1 {main}
thrown in /var/www/liquidata/show_aggregate_holdings.php on line 119